Carbatuss

Generic name:carbetapentane citrate, phenylephrine hydrochloride, guaifenesin
Dosage form: oral liquid
Drug class:Upper respiratory combinations

Medically reviewed by Drugs.com. Last updated on Nov 22, 2021.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION:

Revised Formula
NDC 58809-536-01

Carbatuss is an alcohol-free, red liquid for oral administration having a spearmint odor and flavor.

Each teaspoonful (5 mL) contains:
Carbetapentane Citrate.....20 mg
Phenylephrine Hydrochloride.....10 mg
Guaifenesin.....100 mg

CLINICAL PHARMACOLOGY:

Carbetapentane Citrate is a centrally acting non-narcotic antitussive. Phenyleprine HCl is a sympathomimetic which acts predominantly on alpha receptors and have little action on beta receptors. They therefore function as oral nasal decongestants with minimal CNS stimulation. Guaifenesin has an expectorant action which increases the output of respiratory tract fluid by reducing adhesiveness and surface tension. Sinus and bronchial drainage is improved and dry, nonproductive coughs become more productive and less frequent.

INDICATIONS & USAGE:

For temporary relief of nonproductive cough accompanying respiratory tract congestion associated with the common cold, influenza, sinusitis, and bronchitis.

CONTRAINDICATIONS:

Carbatuss is contraindicated in infants and newborns, and in patients with known hypersensitivity to any of the components. It is also contraindicated in patients with severe hypertension, severe coronary artery disease, hyperthyroidism, and in patients on MAO inhibitor therapy. Patient idiosyncrasy to adrenergic agents may be manifested by insomnia, dizziness, weakness, tremor, or arrhythmias.

WARNINGS:

Sympathomimetic amines should be used with caution in patients with hypertension, ischemic heart disease, diabetes mellitus, increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy. Sympathomimetics may produce central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension.

DO NOT EXCEED RECOMMENDED DOSAGE.